Atrovent HFA
Atrovent HFA (ipratropium bromide) is an anticholinergic bronchodilator administered via a metered-dose inhaler. It is used to prevent bronchospasm in people with COPD. It works by blocking cholinergic receptors in bronchial smooth muscle, leading to bronchodilation.
Dosage by Body Weight
The usual starting dose of Atrovent HFA is two inhalations four times a day. Patients may take additional inhalations as required, but the total number of inhalations should not exceed 12 in 24 hours. Safety and efficacy in pediatric patients under 12 years of age have not been established.
- Body Weight
- Below 5 kg
- Dose
- Not routine / Not recommended
- Frequency
- Use only if prescribed by a specialist
- Tracking Notes
- Safety and efficacy of Atrovent HFA in pediatric patients under 12 years of age have not been established. Not typically used in this weight range.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- Use only if prescribed
- Tracking Notes
- Safety and efficacy are not established. Inhalers are not dosed based on body weight.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- Use only if prescribed
- Tracking Notes
- Consult a pediatric specialist. Safety and effectiveness not established for children.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- Use only if prescribed
- Tracking Notes
- Safety and effectiveness in young children are not established. Dosing is age and condition-based, not weight-based.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- Use only if prescribed
- Tracking Notes
- Consult a physician. Atrovent HFA is typically approved for patients aged 12 years and older.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not routine / Not recommended | Use only if prescribed by a specialist | Safety and efficacy of Atrovent HFA in pediatric patients under 12 years of age have not been established. Not typically used in this weight range. |
| 5-7 kg | Not recommended | Use only if prescribed | Safety and efficacy are not established. Inhalers are not dosed based on body weight. |
| 8-10 kg | Not recommended | Use only if prescribed | Consult a pediatric specialist. Safety and effectiveness not established for children. |
| 11-15 kg | Not recommended | Use only if prescribed | Safety and effectiveness in young children are not established. Dosing is age and condition-based, not weight-based. |
| 16-20 kg | Not recommended | Use only if prescribed | Consult a physician. Atrovent HFA is typically approved for patients aged 12 years and older. |
Formulation
Purpose
Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Generic Name
Ipratropium bromideScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.